Filing Flows

Filing Flows › Companies › Regenxbio › Cash flow

Regenxbio cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$38.4M in Q3 2026 · −$155M over twelve months

Operating cash flow$38.6M
Capital spending−$194K
Free cash flow+$38.4M

Analysis

In Q3 2026, Regenxbio generated $38.6M of operating cash flow and spent $194K on capital projects, leaving free cash flow of $38.4M. That is $94.9M more than in Q3 2025 (−$56.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$152M; the largest uses were operating cash flow ($152M), capital spending ($2.7M); besides operations, cash came from other financing ($100M), other investing ($90.6M); the cash balance rose by $37.0M.

Operating cash flow was $38.6M against net income of −$40.7M. The largest differences: receivables +$98.2M, prepaid and other assets −$36.4M, stock-based pay +$8.1M.

Free cash flow

Regenxbio: free cash flow by quarterRegenxbio: free cash flow by quarter−$32.7MQ4 2024$32.6MQ1 2025−$49.7MQ2 2025−$56.5MQ3 2025−$52.8MQ4 2025−$77.4MQ1 2026−$63.0MQ2 2026$38.4MQ3 2026
Operating cash flow less capital spending.
Regenxbio: operating cash flow against capital spendingRegenxbio: operating cash flow against capital spendingOperating cash flowCapital spending−$31.6M$1.1MQ4 2024$33.6M$1.0MQ1 2025−$49.3M$391KQ2 2025−$56.0M$491KQ3 2025−$52.3M$508KQ4 2025−$76.2M$1.2MQ1 2026−$62.2M$760KQ2 2026$38.6M$194KQ3 2026
Latest (Q3 2026): Operating cash flow $38.6M, Capital spending $194K.

Capital allocation, year by year

Regenxbio: where the cash came from (up) and went (down), by fiscal yearRegenxbio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow $219MFY2021: Shares issued $4.3MFY2021: Capital spending −$84.2M$223MFY2021FY2022: Operating cash flow −$207MFY2022: Shares issued $2.8MFY2022: Capital spending −$30.7M$2.8MFY2022FY2023: Operating cash flow −$218MFY2023: Shares issued $1.5MFY2023: Capital spending −$10.0M$1.5MFY2023FY2024: Operating cash flow −$173MFY2024: Shares issued $133MFY2024: Capital spending −$2.4M$133MFY2024FY2025: Operating cash flow −$124MFY2025: Shares issued $318KFY2025: Capital spending −$2.4M$318KFY2025
Over these 5 years operating cash flow totalled −$504M; the largest uses were operating cash flow ($723M) and capital spending ($130M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$251M
Debtnone
Net cash$251M
Cash runway19 months

Regenxbio is burning cash: its operations consume cash, a free cash flow of −$155M a year at the current rate against $251M of cash and investments: a runway of about 19 months before any new financing.

Where the cash came from and went

Regenxbio: sources (+) and uses (−) of cash, Q3 2026Regenxbio: sources (+) and uses (−) of cash, Q3 2026Other financing$106MOther investing−$86.0MCash drawn (+) / kept (−)−$59.3MOperating cash flow$38.6MShares issued$647KCapital spending−$194K
Regenxbio: sources (+) and uses (−) of cash, TTM to Q3 2026Regenxbio: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$152MOther financing$100MOther investing$90.6MCash drawn (+) / kept (−)−$37.0MCapital spending−$2.7MShares issued$934K

From profit to cash

Regenxbio: net income to operating cash flow, Q3 2026Regenxbio: net income to operating cash flow, Q3 2026Net income−$40.7MDepreciation & amortization$3.5MStock-based pay$8.1MOther non-cash−$22KReceivables$98.2MPayables−$2.0MAccrued liabilities$6.5MDeferred revenue−$3.1MPrepaid and other assets−$36.4MOperating cash flow$38.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$38.6M−$194K$647K−$59.3M$38.4M
Q2 2026−$62.2M−$760K$51K−$21.3M−$63.0M
Q1 2026−$76.2M−$1.2M$146K$19.2M−$77.4M
Q4 2025−$52.3M−$508K$90K$24.3M−$52.8M
Q3 2025−$56.0M−$491K—$20.8M−$56.5M
Q2 2025−$49.3M−$391K$78K$50.5M−$49.7M
Q1 2025$33.6M−$1.0M$150K−$72.6M$32.6M
Q4 2024−$31.6M−$1.1M$38K−$909K−$32.7M

Regenxbio: income statement and cash flow

Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%. The chart follows the revenue to costs, profit and cash.

Regenxbio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.